Every 10-Q that IMAC HOLDINGS INC (BACK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BACK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BACK filings page.
IMAC Holdings, now centered on proteomic cancer diagnostics, reported Q3 2025 net revenue of $0.02 million and a net loss of $3.1 million.
Revenue remains very small while costs are high, producing a negative gross margin and a $0.75 million impairment charge to write off lab equipment whose fair value was determined to be zero. Interest expense rose with new high-discount promissory notes, and total notes payable reached $4.4 million in principal, with $0.5 million unpaid past the November 14, 2025 maturity.
At September 30, 2025, cash was $0.05 million against a $13.0 million working capital deficit and a $13.3 million current liability balance, leading management to state substantial doubt about the company’s ability to continue as a going concern. The company faces Medicare audit overpayment disputes, including a $2.7 million reserve, carries $57.7 million in preferred stock liquidation preference, and discloses multiple material weaknesses in internal control over financial reporting.